The growth-hormone-deficiency-market challenges remain significant despite technological progress. High costs of recombinant human growth hormone therapies continue to limit access in both developed and developing regions. Insurance coverage helps in some countries, but patients in emerging markets often struggle with affordability. Furthermore, treatment regimens involving daily injections discourage adherence, leading to poor outcomes.

Another barrier is underdiagnosis. Many children with GHD are not identified early, and adults often remain untreated due to lack of awareness among both patients and primary care providers. Side effects, variability in individual response to therapy, and regulatory hurdles also contribute to slower adoption rates. Addressing these issues is critical for unlocking the full growth potential of the market.

FAQ:

• Why is adherence a challenge in GHD therapy?

  • Because many treatments require frequent injections, which can be difficult to maintain long-term.